iStar Inc (STAR)
NYSE NYSE Primary Summary
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema
Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development and trials. Competitive positioning is strong, with STAR-0215 outperforming existing treatments like Takhzyro and Haegarda in both efficacy and dosing convenience.
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- Dermata nears completion of enrollment in its DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Raised $5.1 million in gross proceeds from financings completed in 3Q 2024 - SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2024. "The third quarter was a busy time for our team as we approach completing enrollment in our DMT310 Phase 3 STAR-1 study and were able to raise funds, which we believe will allow us to reach the topline data readout in the STAR-1 study in the first quarter of 2025," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer.
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - Dermata continues discussions with potential botulinum toxin partners for DMT410 - Raised $2.3 million in net proceeds from financing completed in 2Q 2024 SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW)("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2024. "We are excited to have enrolled over 50% of patients in our DMT310 Phase 3 STAR-1 trial, and we look forward to the second half of 2024 as our team continues to work diligently to complete enrollment of the DMT310 STAR-1 trial," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer.
iStar Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 55.2 | $8,911.38 | $421.18 | -$8,490.2 | -95.27% |
| SK Sheena Koshy Steadfast Capital Management LP | 13,817.28 | $387,574.7 | $105,425.85 | -$282,148.85 | -72.8% |
iStar Inc (STAR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has iStar Inc ever had a stock split?
iStar Inc Profile
| Diversified REITs Industry | Real Estate Sector | Jay S. Sugarman CEO | NYSE Exchange | 45031U101 CUSIP |
| US Country | 118 Employees | 28 Jun 2024 Last Dividend | 31 Mar 2023 Last Split | - IPO Date |
Overview
iStar Inc. (NYSE: STAR) is an innovative leader focused on revolutionizing the ground lease market. The company's mission is to enhance the value for property owners throughout the United States by providing creative and efficient ground lease solutions for a diverse range of properties. As the originator and primary investment manager—and the largest equity holder—of Safehold Inc. (NYSE: SAFE), which is the first publicly listed company specializing in modern ground leases, iStar plays a critical role in redefining real estate ownership. The firm capitalizes on its extensive experience in finance and net lease structures to further expand its unique operational platform. Known for its relentless pursuit of innovation in the real estate sector, iStar demonstrates excellence in spotting and capitalizing on emerging market opportunities, having successfully managed transactions worth over $40 billion during its two-decade tenure.
Products and Services
- Ground Lease Solutions:
iStar provides innovative ground lease arrangements that enable property owners to optimize real estate assets and unlock new value. These leases are tailored to meet the unique requirements of various types of properties, ensuring that owners receive maximum benefits from their land holdings.
- Investment Management:
The firm serves as a primary investment manager for Safehold Inc., allowing it to supervise and manage investments in modern ground leases. This service helps maximize investment returns and supports the strategic goals of property owners.
- Equity Financing:
iStar acts as the largest equity holder in Safehold Inc., facilitating access to substantial capital resources. This enables both iStar and its clients to engage in larger and more lucrative projects within the real estate sector.
- Market Innovation:
Constantly pushing the boundaries of what is possible in real estate, iStar excels at innovating new business models and market strategies that leverage current trends, ensuring that both the company and its partners stay ahead of the curve.
- Transaction Execution:
With a history of handling more than $40 billion in transactions, iStar offers unrivaled expertise in executing complex real estate transactions, ensuring that all parties achieve favorable outcomes.
